Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: The PROBASE trial

European Urology

Volumn 64, Issue 6, 2013, Pages 873-875

  Arsov, Christian ^a   Becker, Nikolaus ^b   Hadaschik, Boris A ^c   Hohenfellner, Markus ^c   Herkommer, Kathleen ^d   Gschwend, Jürgen E ^d   Imkamp, Florian ^e   Kuczyk, Markus A ^e   Antoch, Gerald ^f   Kristiansen, Glen ^g   Siener, Roswitha ^g   Semjonow, Axel ^h   Hamdy, Freddie C ⁱ   Lilja, Hans ^i,j   Vickers, Andrew J ^j   Schröder, Fritz H ^k   Albers, Peter ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER SCREENING; CLINICAL EVALUATION; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT;

EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84887408056     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.022     Document Type: Editorial

References (10)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. F.H. Schröder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
3. F.H. Schröder, J. Hugosson, and S. Carlsson Screening for prostate cancer decreases metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Eur Urol 62 2012 745 752
4. H. Lilja, D. Ulmert, and T. Björk Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 2007 431 436
5. J. Fang, E.J. Metter, and P. Landis Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging Urology 58 2001 411 416
6. J.A. Antenor, M. Han, K.A. Roehl, R.B. Nadler, and W.J. Catalona Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study J Urol 172 2004 90 93
7. A.J. Vickers, D. Ulmert, and D.D. Sjoberg Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study BMJ 346 2013 f2023
8. L. Dickinson, H.U. Ahmed, and C. Allen Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting Eur Urol 59 2011 477 494
9. C.M. Moore, V. Kasivisvanathan, and S. Eggener Standards of Reporting for MRI-targeted Biopsy Studies (START) of the prostate: recommendations from an international working group Eur Urol 64 2013 544 552
10. J.O. Barentsz, J. Richenberg, and R. Clements ESUR prostate MR guidelines 2012 Eur Radiol 22 2012 746 757